128 related articles for article (PubMed ID: 38299743)
1. Human MARCH1, 2, and 8 block Ebola virus envelope glycoprotein cleavage via targeting furin P domain.
Yu C; Bai Y; Tan W; Bai Y; Li X; Zhou Y; Zhai J; Xue M; Tang YD; Zheng C; Liu Q
J Med Virol; 2024 Feb; 96(2):e29445. PubMed ID: 38299743
[TBL] [Abstract][Full Text] [Related]
2. MARCH8 Inhibits Ebola Virus Glycoprotein, Human Immunodeficiency Virus Type 1 Envelope Glycoprotein, and Avian Influenza Virus H5N1 Hemagglutinin Maturation.
Yu C; Li S; Zhang X; Khan I; Ahmad I; Zhou Y; Li S; Shi J; Wang Y; Zheng YH
mBio; 2020 Sep; 11(5):. PubMed ID: 32934085
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of Viral Glycoprotein Targeting by Membrane-Associated RING-CH Proteins.
Lun CM; Waheed AA; Majadly A; Powell N; Freed EO
mBio; 2021 Mar; 12(2):. PubMed ID: 33727347
[TBL] [Abstract][Full Text] [Related]
4. Host antiviral factors hijack furin to block SARS-CoV-2, ebola virus, and HIV-1 glycoproteins cleavage.
Yu C; Wang G; Liu Q; Zhai J; Xue M; Li Q; Xian Y; Zheng C
Emerg Microbes Infect; 2023 Dec; 12(1):2164742. PubMed ID: 36591809
[TBL] [Abstract][Full Text] [Related]
5. Ebola Virus Requires Phosphatidylserine Scrambling Activity for Efficient Budding and Optimal Infectivity.
Acciani MD; Lay Mendoza MF; Havranek KE; Duncan AM; Iyer H; Linn OL; Brindley MA
J Virol; 2021 Sep; 95(20):e0116521. PubMed ID: 34319156
[TBL] [Abstract][Full Text] [Related]
6. Membrane-associated RING-CH (MARCH) 1 and 2 are MARCH family members that inhibit HIV-1 infection.
Zhang Y; Tada T; Ozono S; Yao W; Tanaka M; Yamaoka S; Kishigami S; Fujita H; Tokunaga K
J Biol Chem; 2019 Mar; 294(10):3397-3405. PubMed ID: 30630952
[TBL] [Abstract][Full Text] [Related]
7. MARCH1 and MARCH2 inhibit pseudorabies virus replication by trapping the viral cell-to-cell fusion complex in trans-Golgi network.
Huang R; Rao CH; Bai YZ; Yu C; Chen M; Peng JM; Xu SJ; Sun Y; Fandan M; Lyu C; Khan M; An TQ; Tian ZJ; Cai XH; Wang G; Tang YD
Vet Microbiol; 2024 Jun; 295():110164. PubMed ID: 38936155
[TBL] [Abstract][Full Text] [Related]
8. Endoproteolytic processing of the ebola virus envelope glycoprotein: cleavage is not required for function.
Wool-Lewis RJ; Bates P
J Virol; 1999 Feb; 73(2):1419-26. PubMed ID: 9882347
[TBL] [Abstract][Full Text] [Related]
9. The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies.
Brinkmann C; Nehlmeier I; Walendy-Gnirß K; Nehls J; González Hernández M; Hoffmann M; Qiu X; Takada A; Schindler M; Pöhlmann S
J Virol; 2016 Dec; 90(24):11075-11086. PubMed ID: 27707924
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the therapeutic effect of antibodies targeting the Ebola glycoprotein using a novel BSL2-compliant rVSVΔG-EBOV-GP infection model.
Lee HN; McWilliams IL; Lewkowicz AP; Engel K; Ireland DDC; Kelley-Baker L; Thacker S; Piccardo P; Manangeeswaran M; Verthelyi D
Emerg Microbes Infect; 2021 Dec; 10(1):2076-2089. PubMed ID: 34674613
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of Ebola Virus Infection via Ficolin-1 Interaction with the Mucin Domain of GP Glycoprotein.
Favier AL; Gout E; Reynard O; Ferraris O; Kleman JP; Volchkov V; Peyrefitte C; Thielens NM
J Virol; 2016 Jun; 90(11):5256-5269. PubMed ID: 26984723
[TBL] [Abstract][Full Text] [Related]
12. A Naturally Occurring Polymorphism in the Base of Sudan Virus Glycoprotein Decreases Glycoprotein Stability in a Species-Dependent Manner.
Lennemann NJ; Dillard J; Ruggio N; Cooney AL; Schaack GA; Davey RA; Maury W
J Virol; 2021 Aug; 95(18):e0107321. PubMed ID: 34232742
[TBL] [Abstract][Full Text] [Related]
13. A GXXXA Motif in the Transmembrane Domain of the Ebola Virus Glycoprotein Is Required for Tetherin Antagonism.
González-Hernández M; Hoffmann M; Brinkmann C; Nehls J; Winkler M; Schindler M; Pöhlmann S
J Virol; 2018 Jul; 92(13):. PubMed ID: 29669839
[TBL] [Abstract][Full Text] [Related]
14. Direct Visualization of Ebola Virus Fusion Triggering in the Endocytic Pathway.
Spence JS; Krause TB; Mittler E; Jangra RK; Chandran K
mBio; 2016 Feb; 7(1):e01857-15. PubMed ID: 26861015
[TBL] [Abstract][Full Text] [Related]
15. Statins Suppress Ebola Virus Infectivity by Interfering with Glycoprotein Processing.
Shrivastava-Ranjan P; Flint M; Bergeron É; McElroy AK; Chatterjee P; Albariño CG; Nichol ST; Spiropoulou CF
mBio; 2018 May; 9(3):. PubMed ID: 29717011
[TBL] [Abstract][Full Text] [Related]
16. Growth-Adaptive Mutations in the Ebola Virus Makona Glycoprotein Alter Different Steps in the Virus Entry Pathway.
Ruedas JB; Arnold CE; Palacios G; Connor JH
J Virol; 2018 Oct; 92(19):. PubMed ID: 30021890
[TBL] [Abstract][Full Text] [Related]
17. Processing of the Ebola virus glycoprotein by the proprotein convertase furin.
Volchkov VE; Feldmann H; Volchkova VA; Klenk HD
Proc Natl Acad Sci U S A; 1998 May; 95(10):5762-7. PubMed ID: 9576958
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the inhibitory effect of an extract of Prunella vulgaris on Ebola virus glycoprotein (GP)-mediated virus entry and infection.
Zhang X; Ao Z; Bello A; Ran X; Liu S; Wigle J; Kobinger G; Yao X
Antiviral Res; 2016 Mar; 127():20-31. PubMed ID: 26778707
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of Viral Glycoprotein Targeting by Membrane-associated-RING-CH Proteins.
Lun CM; Waheed AA; Majadly A; Powell N; Freed EO
bioRxiv; 2021 Jan; ():. PubMed ID: 33532773
[TBL] [Abstract][Full Text] [Related]
20. TIM-1 serves as a receptor for Ebola virus in vivo, enhancing viremia and pathogenesis.
Brunton B; Rogers K; Phillips EK; Brouillette RB; Bouls R; Butler NS; Maury W
PLoS Negl Trop Dis; 2019 Jun; 13(6):e0006983. PubMed ID: 31242184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
